Background and Aims: In the light of growing burden of asthma, there is increasing focus on addressing the barriers and challenges as perceived by asthmatic patients in asthma management. Currently, these barriers and challenges vary widely based on the provision of quality healthcare services. This study was conducted to explore the barriers and challenges faced in asthma management among Malaysian adult asthmatic patients.
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Methods: A qualitative study utilizing face-to-face interviews was conducted with a convenience sample of 17 adult asthmatic patients at two respiratory specialist clinics in Selangor, Malaysia. The socio-demographic characteristics, and medical data were recorded and patients were interviewed using a semi-structured interview guide exploring the barriers and challenges faced by asthmatic patients in asthma management. The transcripts of all the interviews were generated from audio tapes. The tapes were verified for accuracy of transcription and appropriate measures were taken to ensure study rigor and validity. Data obtained were coded independently for the relevant themes and verified by two researchers.
Results: Three main themes of the barriers were identified. These themes were named as patient-related, disease and treatment-related, and healthcare-related barriers. The most frequent types of identified patient-related barriers included: forgetfulness to take controller medicine, feeling stigmatized to use inhaler in public, lack of knowledge regarding asthma management, and limited physical activity because of asthma.
The difficult access to healthcare facility and continuity of care were the most cited healthcare-related barriers; whereas, in disease and treatmentrelated theme the frequently reported barriers included: the inability to avoid allergens, perceived side effects of medicines, and financial limitations. The financial limitations and unavoidable exposure to allergens were two distinct themes identified in the challenges faced by asthmatic patients.
Conclusion:
To improve asthma management and health outcomes, it is critical to identify and address the barriers and challenges as perceived by asthmatic patients. Methods: A prospective observational case control study was carried in which 60 OSA (mild:n=20, moderate:n=20, severe:n=20) and control group (n=20) underwent MRI and lateral cephalometry of UA. Linear Regression analysis (univariate and multivariate linear regression) of various parameters was done to find out the factors correlated with OSA.
Results: In MRI, distance between hyoid bone and posterior nasal spine (H-PNS) and hyoid and posterior pharynx wall near vertebral column (H-COL) was found to be statistically significant (mild= 60.23mm, moderate=68.72mm, severe= 77.26mm: control=60.23mm:p=0.001) and (mild=14.8mm, mod=15.2mm, severe=19.09mm: control=11.5mm: p<0.001). Laterolateral dimension of tongue and lateral pharyngeal wall thickness were found to be statistically significant and increases with severity of OSA. Significant narrowing was found at level 1 i.e rhinopharynx level and low retropalatal oropharynx level i.e. level 3(p<0.001). In lateral cephalometry, distance between hyoid bone and mandibular plane increase with severity of OSA and was found to be statistically significant among all groups (mild=16.68mm,mod=25.25mm,severe=28.1mm:control=16.15mm:p-value <0.001). In univariate analysis, Epworth sleepiness scale (ESS), neck circumference, Modified Mallampati Score, anteroposterior and laterolateral dimension at level 3 and 4, hyoid bone position and laterolateral length of tongue were associated with severity of OSA. In multivariate analysis, the following parameters remained significantanteroposterior and laterolateral dimensions at level3, hyoid bone position, ESS and neck circumference. The aim of our study is to detect the profiles of circulating auto-antibodies and establish a biomarker for IPF with autoimmune features.
Methods: To identify circulating auto-antibodies in IPF, we first performed microarray system constructed by 9,480 human proteins. For this analysis, we used serum samples from five healthy subjects and nine interstitial lung disease (ILD) patients. The most strongly positive autoantibody in the ILD group was chosen to compare the concentration among various ILDs by performing enzyme-linked immuno sorbent assay (ELISA). For ELISA, 13 CTD-ILD samples, 29 IPF samples, 29 NSIP samples, six chronic hypersensitive pneumonia (CHP) samples and 61 healthy subjects were included.
Results: In the microarray analysis, 3971 types of positive autoantibodies on average were detected in the ILD group. Among them, the most strongly positive auto-antibody was against ubiquitin-conjugating enzyme 2T (UBE2T). We performed ELISA for anti-UBE2T antibody (aUBE2Tab) and detected its presence in 92% of CVD-ILD patients (median value: 460.1 ng/ml), 76% of IPF patients (344.1 ng/ml) and 55% of NSIP patients (251.3 ng/ml) while only 17% of CHP patients (166.9 ng/ml) and 16% of healthy control subjects (170.7ng/ml) had a positive result. The area under the curve in ROC for diagnosing CTD-ILD was 87% indicating the spectrum of aUBE2Tab is inclining towards the presence of autoimmunity. However, the association of commercial autoantibodies did not correlate with aUBE2Tab, suggesting the independent ability of aUBE2Tab in detecting autoimmune conditions. In addition, immunohistochemistry observation demonstrated high expression of UBE2T in alveolar epithelial cells from IPF lung tissues.
